Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, Canada.
Division of Geriatric Medicine, School of Medicine, and Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Nat Rev Endocrinol. 2024 May;20(5):261-277. doi: 10.1038/s41574-023-00943-z. Epub 2024 Feb 6.
Sarcopenic obesity is characterized by a concurrent decline in muscle mass and function, along with increased adipose tissue. Sarcopenic obesity is a growing concern in older adults owing to significant health consequences, including implications for mortality, comorbidities and risk of developing geriatric syndromes. A 2022 consensus statement established a new definition and diagnostic criteria for sarcopenic obesity. The pathophysiology of this condition involves a complex interplay between muscle, adipose tissue, hormonal changes, inflammation, oxidative stress and lifestyle factors, among others. Sarcopenic obesity is treated with a range of management approaches, such as lifestyle interventions, exercise, nutrition and medical therapies. Emerging therapies that were developed for treating other conditions may be relevant to sarcopenic obesity, including novel pharmacological agents and personalized approaches such as precision medicine. In this Review, we synthesize the current knowledge of the clinical importance of sarcopenic obesity, its assessment and diagnosis, along with current and emerging management strategies.
肌少症性肥胖的特点是肌肉质量和功能同时下降,同时脂肪组织增加。由于对死亡率、合并症和老年综合征发展风险的影响,肌少症性肥胖是老年人日益关注的问题。2022 年的一项共识声明为肌少症性肥胖确立了新的定义和诊断标准。这种情况的病理生理学涉及肌肉、脂肪组织、激素变化、炎症、氧化应激和生活方式因素等多种因素的复杂相互作用。肌少症性肥胖的治疗方法包括生活方式干预、运动、营养和医疗治疗等多种方法。新兴的治疗方法,如针对其他疾病开发的新型药物和个性化方法,如精准医学,可能与肌少症性肥胖有关。在这篇综述中,我们综合了肌少症性肥胖的临床重要性、评估和诊断以及当前和新兴的管理策略的最新知识。